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Alexander KraevAbstract
Creation of lethal and synthetic lethal mutations in an experimental organism is a cornerstone of genetic
dissection of gene function, and is related to the concept of an essential gene. Common inbred mouse strains
carry background mutations, which can act as genetic modifiers, interfering with the assignment of gene
essentiality. The inbred strain C57BL/6J, commonly known as “Black Six”, stands out, as it carries a spontaneous
homozygous deletion in the nicotinamide nucleotide transhydrogenase (Nnt) gene [GenBank: AH009385.2],
resulting in impairment of steroidogenic mitochondria of the adrenal gland, and a multitude of indirect modifier
effects, coming from alteration of glucocorticoid-regulated processes. Over time, the popular strain has been
used, by means of gene targeting technology, to assign “essential” and “redundant” qualifiers to numerous genes,
thus creating an internally consistent “parallel universe” of knowledge. It is unrealistic to suggest phasing-out of
this strain, given the scope of shared resources built around it, however, continuing on the road of “strain-unawareness”
will result in profound waste of effort, particularly where translational research is concerned. The review analyzes the
historical roots of this phenomenon and proposes that building of “parallel universes” should be urgently made visible
to a critical reader by obligatory use of unambiguous and persistent tags in publications and databases, such as
hypertext links, pointing to a vendor’s strain description web page, or to a digital object identifier (d.o.i.) of the
original publication, so that any research done exclusively in C57BL/6J, could be easily identified.
Reviewers: This article was reviewed by Dr. Neil Smalheiser and Dr. Miguel Andrade-Navarro.
Keywords: Mouse, Inbred strain, C57BL/6J, Synthetic lethality, Gene interaction, Essential gene, Nicotinamide
nucleotide transhydrogenase, Mitochondria, Glucocorticoid hormone, Adrenal glandIntroduction
The concept of an essential gene, whose targeted inactiva-
tion results in lethality of a genetically modified organism,
is a cornerstone of genetic dissection of gene function. Also
important is the derivative concept of synthetic lethality,
wherein inactivation of either of any two genes is not lethal,
but simultaneous inactivation is lethal. Although synthetic
lethality was reportedly discovered in fruit fly Drosophila
as early as in 1922 (historical account [1]), Theodosius
Dobzhansky first made extensive use of it and, indeed,
coined the term. He wrote [2] in his 1945 paper:
“Chromosomes A and B evidently contain genes, or
groups of genes, which taken separately are not lethal
to homozygotes raised at 16.5 degrees, but which be-
come lethal when combined by crossing over. In view
of their known origin by crossing over, chromosomes
Nos. 18, 41, and 63 may be said to carry “synthetic lethals.”
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post-genomic methods of drug discovery [4]. Considerable
progress in analyzing “lethal combinations” [5] has been
achieved in bacteria and yeast [6,7], and in the nema-
tode C.elegans (recent review [8]) but the corresponding
analysis in mammals lags behind.
A major portion of our current knowledge about gene
function in mammals is derived from the phenotypes of
mouse strains with targeted or random gene inactivation
[9]. The mouse research community enjoys the availabil-
ity of an extensive palette of standardized inbred strains,
as well as strains with targeted inactivation/mutation of
specific genes, and many of these are commercially avail-
able from established sources (The Jackson Laboratory,
Charles River, Harlan, Taconic Farms, to name a few).
An ambitious project aimed at inactivation of all predicted
mouse genes is in progress [10]. Even though mouse
models of disease are not limited to targeted gene mutation
or inactivation, the results of studies of the strains produced
by gene targeting technology have made an undisputable
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mon inbred mouse strains carry background mutations
[11-18] that conceivably interact with phenotypes created
by targeted gene disruption, thus possibly interfering with
the assignment of “essential” and “redundant” gene quali-
fiers. Such mutant alleles are among “modifier genes”, the
case of cystic fibrosis CFTR gene being the classical ex-
ample (recent review [19]), some of which are capable of
altering the phenotype of a large number of other muta-
tions. Beside the large number of known modifiers with a
limited effect (recent review [20]), a few point mutations
with implied systemic effect have been uncovered in spe-
cific groups of strains by modest, gene-focused approach
[11-18]. In addition, a much larger number of differences
between the genomes of laboratory mouse strains, mostly
with unclear consequences, have been discovered since
the application of next generation sequencing [21-24].
Genome changes that occurred during the rodent lineage
specification, such as large segmental duplications ([23,24]
and references therein), can now be clearly distinguished
from relatively late changes in the mouse genome that
have occurred since domestication, presumably as the re-
sult of adaptation to a life in captivity and in production
facility [25,26].
The inbred strain C57BL/6J, commonly known, along
with its other substrains, as “Black Six” stands out, as it
carries a homozygous spontaneous deletion in the Nnt gene
[12,27]. The product of this gene [GenBank: AH009385.2],
by virtue of its expression profile [28] directly affects the
function of steroidogenic mitochondria [29] and through
the function of the hypothalamic-pituitary-adrenal axis, ad-
renal response to stress (for a recent succinct review, see
[30]). At the same time, the strain has been used by means
of gene targeting technology to assign “essential” and “re-
dundant” qualifiers to numerous genes. The purpose of this
review is not to raise another concern about the import-
ance of exact mouse nomenclature, but to expose the
particular danger of the Nnt mutation, which, due to its
underappreciated wide systemic effect, has aided in creation
of an internally consistent “parallel universe” of knowledge,
growing at an alarming rate. The review analyzes the histor-
ical roots of this phenomenon and proposes that building
of “parallel universes” should be urgently made visible to a
critical reader by obligatory use of unambiguous animal
strain identifiers in publications and databases, such as
hypertext links pointing to a vendor’s strain description
web page (including stock number), or to a digital object
identifier (d.o.i.) of the original publication.
Review
The power of Black Six
In March 1998, a panel of international scientists met to
make recommendations to the National Institutes of
Health (USA) regarding priorities for generating mousegenomics and genetics resources. A consequence of these
recommendations was the general approval of a strategy
to sequence the mouse genome. The action plan for
mouse genomics was published in Nature Genetics [31].
Although there was considerable debate in the research
community about which mouse strain should ultimately
be used to derive the index mouse genome sequence, the
Coordinating Group unanimously decided on October 5,
1998 that the best choice was the C57BL/6J strain, com-
mercially available from The Jackson Laboratory. The
reason for selecting C57BL/6J out of a palette of other
popular strains was “confidence of strain derivation, wide-
spread use among the research community and favorable
breeding characteristics” [31]. Widespread use of this
strain was, in large part, determined by established tar-
geted mutation technology [32-34], wherein the strain was
routinely used as a host for genetically transformed cells,
derived from a 129-family strain. In 2002, C57BL/6J be-
came the first mouse strain with a sequenced genome, al-
beit with many gaps, and also the first mammalian model
organism with a reference genome. This was carried out
in contrast to the way in which the human genome
sequence was derived [35,36]; the human genome was a
consensus of several genetically distant individuals. In
2009 a new, considerably refined, C57BL/6J genome
sequence was published [23].
These events had a snowball effect and reinforced the
use of the C57BL/6J strain in the mouse research com-
munity. Publications show that many laboratories started
to move their mutant genes of interest to the C57BL/6J
background, even when they may originally have been
obtained in a different strain. In 2013 this strain was
introduced into space research [37,38].
As the great majority of laboratories were not equipped
to make genetically modified strains on their own, but
rather collaborated to create such a strain, borrowed or
purchased it, a logistics pyramid emerged spontaneously
to ensure the widespread use of the C57BL/6J strain through-
out the research community. For a substantial portion
of it there really was no choice in selecting the C57BL/6J
strain due to the existence of the logistics pyramid. More-
over, many in the research community probably did not
care about the reference strain identity and its genetic
background, an impression that can be gleaned from the
frequent absence of strain identity or consistent strain
misspellings in publications.
There was, however, a downside to the widespread use
of C57BL/6J for genetic studies: the phenotype of a
targeted mutation on the C57BL/6J strain sometimes
displayed peculiar characteristics, in particular, where
comparable data on the properties of the same mutation
on a background of another strain were available. One of
the early examples of this kind is the knockout pheno-
type of the glucose-6-phosphate dehydrogenase gene
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not so on the hybrid C57/129 background. In humans,
this gene is one of the most frequently mutated, particu-
larly in African populations, as the reduced activity of
the protein product confers protection from malaria
[40]. From this comparison it could be concluded that
this gene is “essential” only in C57BL/6J, though “redun-
dant” in other strains, or in humans. The authors did
not suspect that they were observing a case of synthetic
lethality. Such discrepancies, which accumulated only
slowly, were usually dismissed, so the fecund and soci-
able C57BL/6J did not stand out in any particularly
unfavorable way at the beginning of the 21st century.
Mutatis mutandis?
Perhaps the first mutation with an implied pleiotropic ef-
fect found in inbred mouse strains was the inactivation of
the gene, encoding aralkylamine N-acetyltransferase,
aanat [11]. The inactivation results in the absence of syn-
thesis of melatonin, a pineal gland hormone [41,42]. While
it affected C57BL/6J and a number of other strains, it was
not immediately apparent how this mutation might stand
in the way of progress, as chronobiology was still in its
infancy. In contrast, the discovery in 2001 of a large gen-
omic deletion in a C57BL/6 lineage, offered commercially
by Harlan, invoked a short, but emotional letter on the
importance of exact strain nomenclature [43]. The im-
portance of adherence to exact strain nomenclature, as
well as the issue of genetic background was, indeed, raised
more than once [44-48] but was largely ignored. In 2005,
Toye et al. [12] found, using a classical genetic mapping
approach, that glucose intolerance in C57BL/6J is largely
due to a naturally occurring “knock-out” of the Nnt gene,
encoding nicotinamide nucleotide transhydrogenase, a
nuclear-encoded mitochondrial proton pump [49]. This
publication invoked a special commentary on the web site
of the strain vendor [50], but did little to alter practices in
the research community. More recent publications [51,52]
showed that a twin strain C57BL/6N did not carry the
Nnt mutation, although it was a descendant of the same
original strain from which C57BL/6J was derived (histor-
ical account [53]). However, gene targeted strains had
been created on both of these backgrounds, often without
explicit knowledge of the differences between them [54].
The Navarro et al. study checked 79 randomly picked
gene-targeted strains deposited to The Jackson Laboratory
and found that 19 of them were homozygous Nnt+/+,
7 heterozygous Nnt+/- and the rest homozygous Nnt-/-.
Sadly, even these discoveries did not appear to sound
an alarm throughout the worldwide mouse community,
and neither did similar publications showing that other
deleterious mutations were present in common mouse
strains (mentioned in the Introduction). The pattern is
recognizable in the public databases and resources, i.e. thecomprehensive mouse embryonic stem cell mutant re-
source by the International Knockout Mouse Consortium
uses the Nnt+/+, strain C57BL/6N [10], while C57BL/6J is
used by the extensive brain-specific gene expression atlas
of the Allen Institute for Brain Science [55] and the three-
dimensional brain MRI atlas [56].
However, behind the scenes, the mouse community be-
came divided into two broad groups. One group contin-
ued to ignore the problem of background mutations,
often reporting inexact or obscure citation of the strain
name, or burying its identity in a chain of references to
the previous papers. The second group of researchers,
recognizing the problem and the potential in comparing
the phenotype on more than one background has started
to move their targeted mutations to another background,
such as the similar, but Nnt+/+ strain C57BL/6N, or to a
distant background, with an attempt to map the genetic
modifiers of the original phenotype.
Publications since 2012 of multiple mouse strain se-
quences derived by next generation sequencing technology
have revealed a number of point mutations and insertions/
deletions in many, if not all, of the popular strains, the
scope of which does not correlate with the apparent
“normality” of the mice [21]. Such discoveries question the
importance of studies of the point mutation of just one
peculiar gene. However, by now substantial data has accu-
mulated that the peculiar properties of certain targeted
mutations on the C57BL/6J background are not seen when
the mutation is expressed on the background of other
popular strains such as FVB/N or 129/Sv, or mixed
(hybrid) mouse backgrounds, or even in the patient, whose
disease was modeled in the mouse. Such examples are too
numerous to be comprehensively included here, without a
bias toward a specific field or research group.
Importantly, strain specificity of gene-targeted mutations
has been seen in such processes as glucocorticoid synthe-
sis [57] and transport [58-61], as well as programmed
cell death [52,62], all known to involve the endoplasmic
reticulum and/or mitochondria. However, while some au-
thors began to suspect the strain background when mouse
model results did not match the results on human patients
with the analogous mutation [63], numerous other authors
did not question the results obtained only on C57BL/6J
[64-72], and some even defended the superiority of this
strain and considered the results obtained on other strains
as problematic [73] a.
Nnt deletion in C57BL/6J has more than one systemic
endophenotype
Independent research in patients has shown that NNT is
the fourth gene associated with familial glucocorticoid
deficiency (OMIM #614736) in humans [29]. This dis-
covery also revealed that de facto, an unplanned inter-
national experiment in the mouse has been going on for
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6J background have unintentionally been combined
pairwise with a pleiotropic mutation, often resulting in
synthetic lethality.
A recent study in four European magnetic resonance
imaging centers found that C57BL/6J also displays spor-
adic porto-systemic shunts (a liver dysmorphology), which
were originally discovered as unexplained spikes of neuro-
transmitter glutamate in its brain [74]. This condition is
also known in humans, and patients with it display
multiple neuro-behavioral problems [75]. This discovery
puts the C57BL/6J strain in the problematic category with
respect to its utility for behavioral studies.
Parallel universes of Black Six biology
The background Nnt mutation in C57BL/6J stands out in
comparison to other known strain-specific mutations
because it affects the so-called hypothalamic-pituitary-
adrenal axis, a complex and incompletely understood
system that regulates multiple processes at the whole or-
ganism level (recent review [76]). Consequently, its effects
may be hard to detect in the reference strain itself in the
absence of “stress” [77,78]. The Nnt mutation ablates a
protein expressed in mitochondria of many tissues [28]
and thus is likely to interact with a large number of other
targeted mutations. Parenthetically, mutations, introduced
by gene targeting, might also be viewed as a form of stress.
The absence of the Nnt protein in steroidogenic mito-
chondria in the adrenal gland results in a multifaceted
phenotype, presumably due to altered corticosteroid sig-
naling, which is, perhaps, still incompletely characterized.
Regardless of the mechanism, it is much more important
that, if a result of gene targeting appeared to be embryonic
lethal in C57BL/6J, the respective targeted gene qualified
as “essential”. On the other hand, if a gene ablation did
not result in lethality, the gene was labeled as “non-essen-
tial” and the respective protein function was considered to
be “redundant”. The scale of this massive misclassification
of genes as “essential” or “redundant” has progressed to
the point of creating a consistent C57BL/6J-specific “par-
allel universe” of knowledge about gene function, a “Black
Six biology”.
Evidently, growth of “parallel universes” could go un-
detected for a long time, as a similar study is not often
done in parallel in different experimental organisms, and
even if discrepancy arises, it can usually be attributed to
“species difference” or, not quite as often, to “genetic
background effects” or to “undocumented confounders”.
The consequences are more serious in the cases where
mouse research produces robust leads for the so-called
“translational research”. The ignorance of the possibility
of the genetic background effects could result in two
scenarios. First, it can make a useless drug go further
into clinical studies, only to be found dangerous in thetoxicity tests. Second, it could preclude a promising drug
from crossing the great translational divide, also known
as the ”Valley of Death” [79-83], separating the pre-
clinical and clinical studies. Both scenarios will likely re-
sult in a profound waste of effort, rather than progress
to a true medical catastrophe.
By extension, this conclusion also applies to other
popular strains having other deleterious mutations,
except that none of the other strains comes close to the
situation with the Nnt mutation in C57BL/6J, if one con-
siders the pleiotropic nature of the lesion and the histor-
ical strain popularity combined.
Recently, a comparative genomic and phenotypic ana-
lysis of the twin strains, C57BL/6J and C57BL/6N, has
been published by a consortium of 18 European labora-
tories [46,53]. While this huge study is much more than
a reiteration of concern about strain nomenclature, it
carefully downplays the scale of the informational conse-
quences of the systemic phenotype(s) of the Nnt muta-
tion and only tentatively suggests that the effect of this
mutation alone could supersede the more modest effects
of the other genomic differences found between these
twin strains.
What should be done?
This review is not an advocacy of a worldwide ban on
C57BL/6J, nor is it a call for massive retraction of publi-
cations using this strain. However, certain pivotal experi-
ments done exclusively on C57BL/6J in the past should
be validated on a progeny of an F1 cross with a distant
strain, to verify that these discoveries do not belong to
“parallel universes” of Black Six biology. By doing so,
one might hope to eventually reap some of the benefits
of the unplanned large scale international experiment
spanning over three decades, wherein numerous gene
targeted mutations have been combined pairwise with
the pleiotropic effect of the Nnt mutation.
The building of the “parallel universes” should and can
be put under control. The important and urgent step
would be to implement a modern mode of tagging of the
available information. Instead of current lax approach, I
would suggest the use of unambiguous strain identifier,
such as a hypertext tag pointing to the vendor’s descrip-
tion web page (if the strain is commercial), or to the
“digital object identifier” (d.o.i.) of the original publication,
if the strain was obtained by other means. Here is how
the strain C57BL/6J could be identified by the hypertext
link: C57BL/6J [http://jaxmice.jax.org/strain/000664.html].
It would be even more appropriate, if a vendor-independent
Reference Laboratory Strain Database could be created,
to which the hypertext links could be directed. For
now, it is within the power of such public databases as
NCBI’s PubMed to introduce an obligatory strain identity
tag on every on-line abstract. Ideally, journal editors should
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the same level of importance as currently applied to
chemical formulae and nucleotide/protein sequences.
Currently, despite the existence of the ARRIVE guide-
lines for animal research [84] that emphasize the im-
portance of correct animal identity, only a few journals
have actually adopted them.
Conclusions
If Hans Selye [85] were alive today, he would have
certainly been deeply concerned by the fact that a mouse
strain with a remodeled stress response and an impaired
hypothalamic-pituitary-adrenal axis is used in the 21st
century as a reference in hundreds of laboratories world-
wide. The altered hypothalamic-pituitary-adrenal axis
response affects not only the assignment of the “essential”
and “redundant” gene qualifiers, on which this review was
deliberately focused, but also non-hereditary mouse
models, such as those with chemically induced conditions.
I can tentatively attribute the pervasive “strain un-
awareness” to at least two dissimilar reasons. The first
reason could be called “shadow of Claude Bernard” [86],
a legacy of physiological paradigms of the 20th century.
Indeed, genetic identity of experimental organism (or
lack thereof ) did not concern physiology for the most
part of the 20th century [87], wherein many fundamental
experiments were done on mongrel dogs. Today, mouse
models are still created within this school of thought.
The second reason is that the unique system of shared
resources and associated institutions in mouse research,
created throughout the 20th century, acts as a powerful
incentive for fallback on a single strain, C57BL/6J. Con-
sequently, suggesting a gradual phasing out of this strain
is unrealistic. This situation is aggravated by the exist-
ence of “twin” substrains, C57BL/6J and C57BL/6N, hav-
ing different systemic mutations [12,18], and by the fact
that even though a study of the Nnt genotype of the
commercially available C57BL/6 substrains has been
published [88], the vendors have yet to follow the ex-
ample of The Jackson Laboratory and Charles River and
include the Nnt genotype in their strain descriptions.
A recent proteomics study [89], comparing the response
of two common mouse strains, C57BL/6J and 129/Sv, to
high-fat diet, is not only a pertinent example of just how
different the same physiological reaction could be in two
distantly related mouse strains, but also an appropriate
test question: which of the two strains should one trust in
anti-obesity drug testing? If one still thinks “C57BL/6J”,
this review has not reached its goal. In this author’s opin-
ion, the correct answer is: the F1 hybrid of the two, since
it precludes the recessive background mutations of either
strain from affecting the outcome.
As for basic research, it is important to understand that
no number of new experiments targeting individual genescan make the “parallel universes” of knowledge quietly van-
ish, but continuing on the road of “strain unawareness”
slowly annihilates a substantial portion of the knowledge
that has been accumulated, creating controversies, going to
the point where trust in mouse as an experimental organ-
ism would falter.
Finally, perhaps, the story of C57BL/6 “twins” could be a
hint that maintenance of an inbred strain for hundreds of
generations is not the best way of assuring consistency.
Today, armed with the refined genome sequence and
contemporary genome analysis tools, geneticists could con-
sider repeated rederivation “from ground up” of an entirely
new, post-genomic, reference strain.
Endnote
aWhile this selection of references constitutes a pos-
sible bias toward specific fields and research groups, the
intention was to provide a sufficient breadth of examples
with potential clinical implications, without excessive
referencing. This selection is by no means complete or
driven by personal reasons.
Reviewers' comments
Reviewer 1 report
Dr. Neil R. Smalheiser, University of Illinois at Chicago,
United States of America
This is a fascinating and scholarly account of “Black Six
biology” with lessons for anyone using inbred mice in biol-
ogy. I think it will be widely read and discussed. However,
I do strongly suggest making a number of changes:
First, the tone of the paper begins as a scholarly discus-
sion, then changes abruptly in the Conclusions section,
becoming negative, polemical and defensive. This posture
is not warranted and will not move readers to the desired
actions. I would remove loaded words such as “shocked”,
“deranged”, “obviously defective”, and “folly”. Moreover, I
disagree that there has been any suppression of dissident
views on the subject of inbred strains. (The long list of ref-
erences cited in this paper, including Wotjak’s paper in the
prominent Trends in Genetics, is evidence to the con-
trary.) I agree that research results often take a long time
to result in changes in behavior: think of how difficult it
was to get physicians to wash their hands between pa-
tients, or to convince scientists to take seriously the threat
of contamination of their cell lines by HeLa. Often infor-
mation is not enough to change behavior, and perhaps
circulating this paper will help, but claiming suppression
will definitely NOT help.
Author's response: I am very grateful to the reviewer for
his critical analysis of the manuscript and constructive com-
ments. Indeed, correct word choice is very important for the
message to reach the audience without alienating anybody. I
have changed the words “shocked”, “deranged”, “obviously
defective” to “deeply concerned”, “remodeled” and “impaired”
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with “strain unawareness”. I removed the reference to sup-
pression of dissident views, which was clearly inadequate.
Minor changes: a) The last sentence of the abstract is
hard to understand, and should be rewritten in plainer
English. b) Is ANY single inbred strain of mouse likely to be
perfect for carrying out knock out experiments? If not, then
you should clarify better that it is not 6J that is the problem,
but the lack of robustness built into the experiments (i.e.
perhaps lethality should be an outcome averaged over a
number of diverse strains?). Statements such as “interfering
with the assignment of “essential” and “redundant” gene
labels” (p. 3) or “massive misclassification of proteins as
“essential” or “redundant” (p. 9) should be changed, since
any assignment is relative to some choice of strain and some
background genome. c) Please define synthetic lethality
(p. 6). d) The term “judicial” (p. 11) is obscure and should
be replaced with something easier to understand.
Author's response: Although the suggestions are listed
by the reviewer as minor, they prompted me to rewrite
portions of the Introduction and move a portion from the
Conclusions into a new section, particularly that similar
concerns were raised by the other reviewer. Specifically,
a) the last sentence in the revised Abstract now reads:
“…proposes that building of “parallel universes” should be
urgently made visible to a critical reader by obligatory use
of unambiguous and persistent tags in publications and
databases, such as hypertext links, pointing to a vendor’s
strain description web page, or to a digital object identifier
(doi) of the original publication, so that any research done
exclusively in C57BL/6J, could be easily identified.”
b) The short answer is that no single current strain is
perfect for all conceivable knockout experiments, however,
giving practical advice on strain selection was not the
purpose of my review, instead, the focus is on the legacy of
“strain unawareness”. I stand by the idea that the legacy of
strain unawareness is massive functional misclassification
of genes. Besides, since controls for background-specific
phenomena (including lethality), such as outcross to a gen-
etically distant strain are often not done, indeed there is
also a common lack of robustness in mouse experiments,
presumably dictated by their cost. However, while technic-
ally gene essentiality assignment always refers to a specific
(genetic) background, as long as it is currently accepted
that core physiology of all mammals is the same, conse-
quently certain genes should be essential in mammals
regardless of background.
c) expanded historical background and a definition of
synthetic lethality is now provided in the Introduction.
d) word “judicial” was replaced by “modern mode”.
Reviewer 1 report on the revised version
The paper is improved and reads well. I would suggest
making a few minor changes of wording: a) In thesection What Should be Done?, I would remove the
phrase "as some of my previous reviewers have sug-
gested". b) In the section Conclusions, "Had Hans Selye
been alive" is improper grammar [certainly he had been
alive]. Maybe say something like, If Hans Selye were
alive today,.... c) In the third paragraph of Conclusions, I
would rephrase or remove the first sentence (that in-
cludes "medicine is not in immediate danger of the inva-
sion of newdrugs,…).
Author's response: I accept all of the reviewer’s sugges-
tions. The text has been changed to accommodate them.
Reviewer 2 report
Dr. Miguel A. Andrade-Navarro, Max Delbrück Center
for Molecular Medicine, Germany
The manuscript from Kraev points to a serious issue af-
fecting 30 years of research in mouse genetics: the wide-
spread use of the inbred strain C57BL/6J (or Black Six)
with known and often ignored genetic and physiological
defects, and the failure of many reports to indicate
whether they use this or other mouse strains. As a result,
the relevance of many published experimental results
remains questionable until these experiments are repeated
in mouse strains of “more robust” genetics. The author
proposes that mouse strains should be clearly annotated
in publications, and that the use of Black Six for genetics
research should be carefully considered. While, as he ad-
mits, he is not the first to state these claims, this manu-
script collects the bibliography relevant to the problem
and insists on the annotation approach.
Major comments
The author needs to be more clear about whether he
proposes that mouse strains must be tagged, or some
strains not be used, or what. I think he suggests both
and then this should be stated in the abstract.
Author's response: I am grateful to the reviewer for in-
depth analysis of the manuscript and many constructive
suggestions. I do suggest that mouse strains should be
more clearly tagged in publications, but I do not suggest
any kind of prohibition on certain strains. Rather, the au-
thors should be aware of the background mutations and
their possible effect on their studies. Ideally, more than
one strain should be used to evaluate a newly discovered
effect of a targeted gene modification (knock-in or knock-
out), particularly the one that results in lethality.
The technical details of how to annotate mouse strains
in future and past manuscripts are loosely defined as
“hypertext tagging”. In the absence of a deeper discussion
on how the annotations will be achieved, I suggest to be
simpler and I would change the sentence in page 2: “by
obligatory hypertext tagging of proper use, as well of as
misuse and omission, of exact animal strain names in
publications and databases.” to “by obligatory tagging of
exact animal strain names in publications and databases.”
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revised text, I give specific suggestions. Please also see
below the response to “Page 4” comment on the proposed
format of the strain tag.
Also in page 11, I would simplify “This should start
with biomedical literature, so that experiments done ex-
clusively on C57BL/6J are clearly tagged with hypertext
links and become identifiable for subsequent machine
analysis.” to “This should start with biomedical litera-
ture, so that experiments done exclusively on C57BL/6J
are clearly tagged.”
Author's response: I agree with this suggestion, the
Abstract and the body of the text have been changed to
accommodate it.
Then, the author might need to be more specific about
whom is he addressing: are journal editors supposed to
enforce the proper description of mouse strains in new
papers? Should researchers stop using certain strains for
particular topics of research? Should database centers
like the NCBI and the EBI back-annotate existing biblio-
graphic records (e.g. MEDLINE) to include missing
strain annotation? Should authors of published literature
contribute to annotate their database records?
Author's response: Ideally, journal editors should be the
ones to elevate obligatory strain designation to the same
importance level as chemical formulae and nucleotide/
protein sequences. Strain identity is one of the central is-
sues in the ARRIVE guidelines, published in 2010, which
are, admittedly, voluntary, and are currently supported by
only a few journals. In this review, I did not plan to elabor-
ate on which strains are bad choices for specific fields of
research, it is an attractive topic for more focused future
publications. It would certainly be desirable that database
centers back-annotate existing bibliographic records, but
this needs a specialized discussion, which hopefully follows
after the publication of this review. The back-annotation
would obviously be incomplete without active participation
of the authors of the original research.
Regarding database records, there are already MeSH
terms for mouse strains that are used to annotate records
in MEDLINE. See for example term: Mice, Inbred C57BL
[B01.050.150.900.649.865.635.505.500.400.420]. There are many
others that the author could examine at: http://www.nlm.
nih.gov/cgi/mesh/2014/MB_cgi?mode=dcms&term=Mice,+
Inbred+Strains&field=entry#TreeB01.050.050.157.520
If the author thinks that these terms are incomplete
then he could say so and suggest how these terms should
be completed.
Author's response: I have expanded a portion of the
Conclusions into a separate section to discuss this point.
Indeed, relevant MESH terms are useful, but they are in
need of update. The reference, suggested by the reviewer,
contains MESH terms for only a few most common
mouse strains, but does not allow distinction between thestrains of the C57BL family, two of which are the topic of
this review.
Page 4: “The purpose of this review is not to raise
another concern about the importance of exact mouse
nomenclature, but to expose the particular danger of a
single mutation, which has aided in creation of an in-
ternally consistent parallel universe of knowledge. I sug-
gest a simple way to stop this trend.” May be it would
help here to explain shortly what the suggestion is.
Author's response: I created a new subsection to elabor-
ate on this point. Essentially, it amounts to the use of
unambiguous strain identifier, such as a hypertext tag
pointing to the vendor’s description web page (if the strain
is commercial), or to the “digital object identifier” (doi) of
the original publication, if the strain was obtained by other
means. Here is how the strain C57BL/6J would be identi-
fied by the hypertext link: C57BL/6J [http://jaxmice.jax.
org/strain/000664.html].
Page 9. While I am sympathetic with the point being
made, I am not sure to agree with the dramatic example
given in page 9: “if a new drug for human consumption
were suggested as a result of experimentation in C57BL/6J
alone [?]”. There are so many differences between mice
and humans that I doubt the “abnormalities” of Black Six
would specifically result in dangerous drugs. In general I
would here just insist on the danger of extracting conclu-
sions on booby-trapped genetic backgrounds.
Author's response: The anticipation of dramatic conse-
quences, possibly associated with this problem, hinges on
how much one believes in the existence of the great trans-
lational divide, also known as the“Valley of Death”,
which separates pre-clinical studies from the clinical
ones. I expanded this portion into suggesting that the sys-
temic defect, such as glucocorticoid deficiency, can both
make a seemingly promising drug to go further into clin-
ical studies and subsequently rejected, as well as, more
importantly, make an actually promising drug to fail in
animal studies, and thus prevent it from crossing the
translational divide. Either outcome will likely result in a
wasted effort, rather than invoke a medical catastrophe,
so, indeed, the original drama was exaggerated.
Minor comments
The first sentence in abstract and introduction are the
same. This is a bit distracting. I would change either.
Author's response: The phrases have been changed.
Page 3: “Even though mouse models of disease are not
limited to targeted gene mutation or inactivation, it has
made an undisputable impact on biology and medicine.”
This sentence is not clear. What is “it” referring to?
Author's response: This phrase appeared as an error of
article shortening. I am grateful to the reviewer for pointing
to the ambiguous phrase, which has been corrected.
A number of references seem not to be cited in the main
manuscript and could be removed from the reference list.
Kraev Biology Direct 2014, 9:18 Page 8 of 10
http://www.biologydirect.com/content/9/1/18In the current version these are Ref 16 (page 3), Refs
30-31 (page 5), Ref 43 (page 6),
Author's response: Orphan references were removed and
the reference list is updated to reflect the revised text.
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